Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

• Main Authors: Keech, A.C, Scott, R., Best, J.
• Other Authors: SURGERY
• Format: Article
• Published: 2020
• Subjects: antidiabetic agent; fenofibrate; high density lipoprotein; high density lipoprotein cholesterol; low density lipoprotein cholesterol; peroxisome proliferator activated receptor agonist; placebo; triacylglycerol; antilipemic agent; apolipoprotein B; cholesterol; adult; aged; article; clinical trial; controlled clinical trial; controlled study; coronary risk; double blind procedure; drug mechanism; female; high risk patient; human; hypertension; ischemic heart disease; long term care; major clinical study; male; metabolic syndrome X; non insulin dependent diabetes mellitus; obesity; randomized controlled trial; treatment outcome; waist circumference; Australia; blood; cardiovascular disease; coronary artery disease; diabetes mellitus; Finland; middle aged; New Zealand; Aged; Apolipoproteins B; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Placebos; Triglycerides
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/178030
• Institution: National University of Singapore

10.1186/1475-2840-4-13